肺内T细胞足以治疗schistosoma诱导的肺高血压
Dara C Fonseca Balladares1, Biruk Kassa1, Claudia Mickael2
1Lung Biology Center, Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA.
International journal of molecular sciences
|September 14, 2024
概括
阻断T细胞迁移并没有预防发生杆菌病引起的肺高血压 (PH). 肺血管中的记忆CD4T细胞足以引起PH,即使没有局部炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
- 心血管研究研究心血管研究
背景情况:
- 螺杆体病是一种寄生性疾病,可以导致肺高血压 (PH).
- Th2 CD4 T 细胞对于实验性瘤诱导的PH至关重要.
- 对于T细胞迁移到肺部在发起局部炎症和PH中的血管重塑中的作用仍然不清楚.
研究的目的:
- 为了调查阻断T细胞向肺部迁移是否会影响Schistosoma诱导的肺高血压的发展.
- 要确定T细胞在肺血管中的存在是否足以引起PH.
主要方法:
- 小鼠对Schistosoma mansoni蛋敏感,并通过尾静脉注射进行挑战.
- FTY720用于阻断淋巴细胞从淋巴结的退出.
- 量化了T细胞种群,PH严重程度和细胞因子水平.
主要成果:
- FTY720治疗减少了外围T细胞,但没有改变PH或2型炎症.
- 肺T细胞数量保持不变,尽管FTY720的管理.
- 仅仅通过对卵子的敏感化就会增加血管内T细胞,包括记忆细胞,而不会引起显著的PH或炎症.
结论:
- 抑制T细胞迁移并没有抑制Schistosoma诱导的PH.
- 肺的血管内空间中的记忆CD4 T细胞足以诱发2型炎症和PH.
相关概念视频
Pulmonary Tuberculosis II
214
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
214
Pulmonary Hypertension: Classification and Pathogenesis
158
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
158
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147


